If You Invested in AgomAb Therapeutics NV (AGMB)
Looking for the current price? See the AGMB quote & overviewWhat $1,000 or $10,000 in AGMB Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Feb 6, 2026 |
|---|---|---|---|---|
| $1,000 | — | — | — | $854 -15% |
| $10,000 | — | — | — | $8,539 -15% |
Based on real historical closing prices, dividend- and split-adjusted, through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for AGMB$1,000 Investment Over Time
AGMB vs S&P 500Year-by-Year Returns
AGMB annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2026 | $14.65 | $12.51 | -14.6% | -14.6% |
About AgomAb Therapeutics NV
Healthcare · NASDAQ
Agomab Therapeutics NV (AGMB) develops disease-modifying therapeutics for fibro-inflammatory, immunology, and inflammatory diseases. The company is a clinical-stage biopharmaceutical issuer headquartered in Antwerp, Belgium, and its American Depositary Shares trade on the Nasdaq Global Select Market under the symbol AGMB. Each ADS represents one common share of Agomab.
Agomab's research and development model centers on chronic fibrotic indications and therapies designed to target established biological pathways. Its product candidates use small-molecule and antibody approaches, including organ-restricted strategies intended to focus activity in affected tissues. The company describes its program focus as resolving fibro-inflammation and restoring organ function in diseases associated with fibrosis.
The company's disclosed pipeline includes ontunisertib, also known as AGMB-129, and AGMB-447. Ontunisertib is being developed in fibrostenosing Crohn's disease, a fibrotic complication of inflammatory bowel disease. AGMB-447 is an investigational inhaled, lung-restricted small molecule inhibitor of ALK5, also referred to as TGFβR1, in development for idiopathic pulmonary fibrosis. Agomab has reported U.S. composition-of-matter patent coverage for AGMB-447.
As a development-stage biopharmaceutical company, Agomab's operating activity is focused on pre-commercial research and clinical development rather than commercial product sales. Its recurring corporate disclosures address clinical-program progress, intellectual-property protection, regulatory interactions, research and development spending, financing activity, and governance matters. Agomab completed its initial public offering of ADSs in February 2026, establishing AGMB as a publicly traded foreign private issuer in the United States.
Frequently Asked Questions
AgomAb Therapeutics NV investment returns
How much would $1,000 invested in AgomAb Therapeutics NV be worth today?
Limited historical data is available for AGMB. The stock has been trading since 2026-02-06.
Has AgomAb Therapeutics NV outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare AGMB performance over available time periods.
What is AgomAb Therapeutics NV's average annual return?
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
